Background and Aim: Women who are homozygous for the p.C282Y mutation in the HFE gene are at much lower risk of iron overload-related disease than p.C282Y homozygous men, presumably because of the iron-depleting effects of menstruation and pregnancy. We used data from a population cohort study to model the impact of menstruation cessation at menopause on serum ferritin (SF) levels in female p.C282Y homozygotes, with p.C282Y/p.H63D simple or compound heterozygotes and those with neither p.C282Y nor p.H63D mutations (HFE wild types) as comparison groups. Methods: A sample of the Melbourne Collaborative Cohort Study was selected for the "HealthIron" study (n = 1438) including all HFE p.C282Y homozygotes plus a random sample stratified by HFE-genotype (p.C282Y and p.H63D). The relationship between the natural logarithm of SF and time since menopause was examined using linear mixed models incorporating spline smoothing. Results: For p.C282Y homozygotes, SF increased by a factor of 3.6 (95% CI (1.8, 7.0), P < 0.001) during the first 10 years postmenopause, after which SF continued to increase but at less than half the previous rate. In contrast, SF profiles for other HFE genotype groups increase more gradually and did not show a distinction between premenopausal and postmenopausal SF levels. Only p.C282Y homozygotes had predicted SF exceeding 200 μg/L postmenopause, but the projected SF did not increase the risk of iron overloadrelated disease. Conclusions: These data provide the first documented evidence that physiological blood loss is a major factor in determining the marked gender difference in expression of p. C282Y homozygosity.
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Introduction
Hereditary hemochromatosis is an iron overload disorder with clinical complications resulting from the deposit of excess iron throughout the body. The health consequences can be serious, with untreated cases at risk of hepatic cirrhosis and hepatocellular carcinoma. [1] [2] [3] [4] The discovery of the HFE gene in 1996 identified homozygosity for the p.C282Y HFE mutation as the major risk factor for hemochromatosis, which accounts for over 90% of clinical cases. 5 Genetic susceptibility is most common among people of Northern European descent, with at least 1 in 200 homozygous for the p.C282Y mutation. The phenotypic expression or penetrance of p.C282Y homozygosity for both elevated serum iron indices and disease manifestations is incomplete. That is, many p.C282Y homozygotes do not develop iron overloadrelated disease. 1 Epidemiological studies have consistently shown a relationship between p.C282Y homozygosity and elevated body iron stores, with elevated serum ferritin (SF) concentration (a sensitive indicator of body iron stores 3, 4 ) found in 40-60% of female homozygotes and 75-100% of male homozygotes. 1, 6 The lower incidence of elevated iron in women compared with men has been widely attributed to the iron-depleting effects of menstrual blood loss and pregnancy, 5, 7 as suggested by a number of studies showing that premenopausal women have lower SF levels than postmenopausal women and men. [7] [8] [9] [10] [11] [12] Some studies have reported increases in SF levels after menopause followed by a plateau at 6-10 years, 9-11 but these studies did not stratify by HFE genotype. Moreover, they provided only descriptive results by plotting SF levels against categorical time intervals since menopause, or used regression models that did not go beyond testing for linear trends. No study has previously compared premenopausal and postmenopausal iron loading stratified by HFE genotype including a comparison group representing the general population. Elucidating this relationship may suggest reasons why p.C282Y homozygous women are at low risk of iron overload-related disease.
We investigated the relationship between time since menopause and SF concentration and whether this varies between HFE genotypes: p.C282Y homozygotes, p.C282Y/H63D compound heterozygotes (at intermediate risk of iron overload 13 ), and the remaining three HFE genotype groups (p.C282Y and p.H63D heterozygotes and p.H63D homozygotes). The latter three groups confer no increased risk of iron overload compared with those with no HFE mutations. 2, 6, 14, 15 This was achieved by using data from female participants in the "HealthIron" study.
Methods
The Melbourne Collaborative Cohort Study. Between 1990 and 1994, 41 514 people (24 469 females) aged between 27 and 75 years (99% aged 40 to 69 years) were recruited to the Melbourne Collaborative Cohort Study (MCCS). 16 Participants were recruited through the Australian Electoral Roll (voting is compulsory in Australia) and as part of the study completed a questionnaire about diet, lifestyle factors, medical history, and reproductive history (for women), had a physical examination, and provided a fasting blood sample.
The HealthIron study. Beginning in 2004, blood samples from 31 192 MCCS participants (17 951 female) of Northern European descent were genotyped for the p.C282Y mutation. Those with one copy of the p.C282Y mutation were then genotyped for the p.H63D mutation and classified as simple (one copy of the p.C282Y mutation) or compound (one copy each of the p.C282Y and p.H63D mutations) heterozygotes. All 203 participants homozygous for the p.C282Y mutation (108 female) were invited to attend HealthIron follow-up clinics, together with a random sample stratified by HFE genotype, including 242 compound heterozygotes (125 female) and 361 participants (197 female) wild type for both mutations. Of the 1438 subjects invited, 269 were lost to follow-up, and 113 were deceased, leaving 1056 in the study and an overall participation rate of 73.2% or 79.4% excluding those already deceased.
HealthIron follow-up clinics were held between 2004 and 2006. Participants completed a questionnaire on medical history (including diagnosis and treatment of hemochromatosis), blood donation, and reproductive history for women. Participants also underwent a physical examination, provided a blood sample and provided a cheek brush swab to confirm baseline HFE genotype. Blood samples were paired for analysis with stored baseline samples collected between 1990 and 1994 for each participant and analyzed for SF, transferrin saturation, and a selection of liver enzymes. 1 All participants gave written informed consent to participate in both the MCCS and the HealthIron sub-study. Both protocols were approved by the Cancer Council Victoria's Human Research Ethics Committee.
Definitions and exclusion criteria. Menopausal status and age at menopause were assessed at baseline and follow-up by asking women whether they had had a menstrual period in the last 12 months, and if not, how old they were at their last menstrual period and the reason their menstrual periods ceased (naturally, hysterectomy, other). If women were postmenopausal or had had a hysterectomy before baseline, they were not asked again at follow-up.
Time since menopause was calculated as the number of years between a women's age at baseline (or follow-up) and her reported age at natural menopause or hysterectomy. In subsequent analyses, we considered time since natural menopause and time since hysterectomy equivalent in that both result in the cessation of regular menstrual blood loss and were therefore physiologically equivalent.
All analyses were stratified by four groups of HFE genotype: p. C282Y homozygote, p.C282Y/H63D compound heterozygote, other HFE genotype (includes p.C282Y heterozygotes, p.H63D heterozygotes, and p.H63D homozygotes), and HFE wild type (neither p.C282Y nor p.H63D mutation). For all analyses, we used HFE wild types as the control group because of their low risk of iron overload. Any SF measurements from participants made after therapeutic venesection were excluded from analyses.
Statistical methods. The relationship between the natural logarithm of SF (log(SF)) and time since menopause was examined using linear mixed models. 17 This incorporated both spline smoothing 18 and correction of parameter estimates, and their standard errors, for repeated measures at baseline and follow-up separately for each HFE genotype group, excluding measurements post-venesection. These models were used to generate curves for the mean predicted SF levels (with 95% confidence intervals) from 10 years premenopause to 30 years postmenopause for each HFE genotype group. To quantify the change in SF levels postmenopause, the ratio of mean predicted SF level postmenopause to mean predicted SF level at menopause (the SF ratio) was calculated by exponentiating the difference in the corresponding postmenopause and menopause log(SF) values at intervals postmenopause of 5, 10, 15, and 20 years. All analyses were performed in Stata version 13.1.
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Results
Across all HFE genotype groups, 692 women participated in the HealthIron study. Nineteen p.C282Y homozygotes and one p. C282Y/H63D compound heterozygote were excluded because of being therapeutically venesected during the study period, leaving 89 p.C282Y homozygotes, 124 compound heterozygotes, 197 HFE wild types, and 262 other HFE genotypes available for analysis. Table 1 shows the characteristics of selected variables across HFE genotype groups for the 672 women included in the analytic sample, of which 539 were postmenopausal at follow-up. The mean age of women at baseline, menarche, and age of menopause were similar for the four HFE genotype groups. Similarly, there was no statistically significant difference in the number of postmenopausal women at follow-up between the genotype groups. Table 2 shows estimated SF ratios at 5-year intervals postmenopause for each of the four HFE genotype groups. For p.C282Y homozygotes, SF rose by a factor of 3.6 (95% CI (1.8, 7.0), P < 0.001) after the first 10 years postmenopause, after which SF continued to increase but at less than half the previous rate (Table 2 and Fig. 1 ). In contrast, SF profiles for other HFE genotype groups (Table 2 and Fig. 1 ) increased only gradually and did not show a distinction between premenopausal and postmenopausal SF levels. Only p.C282Y homozygotes had predicted SF exceeding 200 μg/L postmenopause, but based on previously reported analyses from the same cohort, the projected SF did not increase the risk of iron overload-related disease. 20 This analysis could not examine SF changes in detail during the 5-year window after menopause because the mean age of postmenopausal women at baseline was 61 years (SD = 5), and consequently, baseline SF measurements were taken on average 11 years after menopause (SD = 6).
Discussion
This is the first longitudinal study to investigate the role of menstruation cessation in iron accumulation, as measured by SF, in women with a genetic pre-disposition to iron overload-related disease. This was achieved by analyzing longitudinal data from female participants in the HealthIron study to examine differences in the trajectory of premenopausal and postmenopausal SF levels between HFE groups. The results of spline smoothing of the logarithm of SF concentration against time since menopause suggested that there was no evidence of SF increasing substantially beyond 5-10 years after menopause or hysterectomy in each HFE group and that the majority of postmenopausal iron-loading occurred near the time of menopause.
The observation that women accumulate iron once their regular menstrual cycles finish is well documented in population studies from Australia, the USA, France, the UK, and Denmark. 7, 8, [10] [11] [12] A small number of studies have described the association between SF and time since menopause or hysterectomy, yet none have explored this relationship between different HFE genotypes. An analysis by Liu et al. 21 of single SF measurements from 620 postmenopausal women in the Nurse's Health Study found time since menopause was linearly associated with higher SF concentrations when controlling for age, body mass index (BMI), physical activity, dietary factors, and excluding women who had used postmenopausal hormones. Whitfield et al. 11 analyzed single blood samples from 2039 women in the Australian Twin Registry reporting that SF increases above premenopausal levels in the first 5 years after menopause, before reaching a plateau at approximately 6-10 years. In a study of single measurements of iron indices from a random sample of 1359 Danish women, 10 a similar trend of rapid SF increase in the first 5 years after menopause before a leveling out at 6-10 years was reported. A significant correlation (r = 0.18) between SF and the number of postmenopausal years in non-blood donors was found. The authors noted similar SF levels were seen when studying healthy 85-year-old women in Copenhagen County 22 and suggested that after ¶ Comparison mean age at menopause HFE wild type and Other HFE P = 0.009, although times to menopause were not statistically significantly different using the log-rank test to compare either p.C282Y/H63D compound heterozygotes (P = 0.48) or p.C282Y homozygotes (P = 0.85) to Other HFE genotypes (p.C282Y heterozygotes, p.H63D heterozygotes and p.H63D homozygotes).
7-10 years of postmenopausal iron accumulation, SF levels stabilize to their new steady-state level and remain fairly constant. This idea has also been put forward by Garry et al. 9 that an individual's "theoretical set point of iron stores" occurs around the age of 40 years for men and after menopause for women. They discuss this in light of their finding that age was associated with SF in a cross-sectional analysis of 276 postmenopausal women when adjusting for BMI and dietary factors, arguing that not enough time had elapsed for postmenopausal women to reach their steady-state iron level. Previous studies have reported that age, alcohol intake, BMI, and energy intake are positively correlated with SF levels in postmenopausal women, whereas blood donation/therapeutic venesection and hormone replacement therapy are negatively correlated with SF levels. 8, 9, 11, 21, [23] [24] [25] The effect of dietary heme-iron intake on SF remains controversial; the UK Women's Cohort Study, 8 Nurses' Health Study, 21 and a Danish cohort study 24 reported positive correlations, yet longitudinal and crosssectional analyses of participants in the New Mexico Aging Process Study 9 reported no relationship. Extending the statistical methods used here to accommodate covariates when generating SF profiles will be the subject of future research.
One potential limitation of this study was the possibility that individuals with iron overload-related disease were less likely to participate in follow-up. However, there is good evidence that this was not the case, given that participation rates were comparable between p.C282Y homozygotes (72%) and the overall cohort (73%), and the similarity of baseline iron indices between participants (male and female) lost to follow-up (data not shown). The use of self-reported age at menopause was considered appropriate given that menopause was well defined in the questionnaire and is a significant life event the timing of which most women would be expected to remember.
In conclusion, our demonstration that SF approaches steadystate levels 5-10 years after menopause in all HFE groups offers an explanation as to why female p.C282Y homozygotes remain at low risk of iron overload-related disease. It is acknowledged that the iron depleting effects of menstruation and pregnancy result in female homozygotes not being exposed to elevated SF levels until much later in life. 7 Our study extends this finding by showing that while steady-state SF levels after menopause were higher in p. C282Y homozygotes than in other HFE genotypes, there was no evidence that SF levels increased beyond this point. This pattern of postmenopausal iron accumulation is similar to that reported for non-genotyped study populations 10, 11 and is consistent with the notion that iron accumulation is physiologically self-limiting and that women reach their steady-state iron levels after menopause 3,9,26 even if age rather than the interval since menopause is used as the time scale. 27 The observation that SF levels plateau at steady-state levels in male and female p.C282Y homozygotes, 28, 29 combined with growing evidence that female homozygotes do not reach this point until about 10 years after menopause, or at roughly 60 years of age, suggests that female homozygotes have approximately 20 years less exposure to elevated iron stores than male homozygotes. It is, therefore, plausible that female homozygotes are not exposed to elevated SF levels for long enough to ever put them at increased risk of iron overload-related disease.
